Breast (Oct 2024)

Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study

  • Caterina Caminiti,
  • Giuseppe Maglietta,
  • Laura Arenare,
  • Raimondo Di Liello,
  • Gessica Migliaccio,
  • Daniela Barberio,
  • Michelino De Laurentiis,
  • Francesca Di Rella,
  • Francesco Nuzzo,
  • Carmen Pacilio,
  • Giovanni Iodice,
  • Michele Orditura,
  • Fortunato Ciardiello,
  • Sara Di Bella,
  • Luigi Cavanna,
  • Camillo Porta,
  • Filippo Giovanardi,
  • Carla Ida Ripamonti,
  • Domenico Bilancia,
  • Giuseppe Aprile,
  • Tommaso Ruelle,
  • Francesca Diodati,
  • Maria Carmela Piccirillo,
  • Elisabetta Iannelli,
  • Carmine Pinto,
  • Francesco Perrone

Journal volume & issue
Vol. 77
p. 103781

Abstract

Read online

Patients’ self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients.Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) are a tool allowing direct patients’ reporting of side-effects.We tested psychometric properties of a selected list of PRO-CTCAE items, in a cohort of 303 breast cancer patients, using validated instruments for quality of life assessment as anchors.The analysis of convergent validity with HADS (Hospital Anxiety and Depression Scale) and EORTC BR-23 sub-scales, and the analysis of responsiveness with the PGIC (Patients Global Impression of Change) score supported that a selected list of PRO-CTCAE symptoms might represent a standardized, agile tool for both research and practice settings to reduce patient burden without missing relevant information on patient perceptions.Among patients using digital devices, those with a higher education levels required shorter time to fulfil questionnaires.In conclusion, a selected list of PRO-CTCAE items can be considered as a standardized, agile tool for capturing crucial domains of side-effects and quality of life in patients with breast cancer.The study is registered on clinicaltrials.gov (NCT04416672).

Keywords